Generally mild/moderate nonserious adverse events in PsA patients treated with tofacitinib

Key clinical point: Patients with psoriatic arthritis (PsA) who received treatment with tofacitinib experienced mostly mild/moderate nonserious adverse events (AE), which persisted for a shorter duration and had a minimum effect on the continuation of tofacitinib treatment.

Major finding: In the first 3 months of treatment, the most frequent nonserious AEs were headache (incidence rate [IR] 16.9-39.2) and diarrhea (IR 15-17) and duration of such AEs was ≤4 weeks with none leading to permanent discontinuation of treatment.

Study details: Findings are from a post hoc analysis of phase 3 studies including 710 patients with active PsA who received 5 mg tofacitinib, 10 mg tofacitinib, or placebo and had a previous inadequate response to ≥1 conventional synthetic disease-modifying antirheumatic drug or ≥1 tumor necrosis factor inhibitor.

,

Disclosures: This study was funded by Pfizer. Five authors reported being employees and stockholders of AbbVie. The other authors reported ties with several sources including AbbVie.

Source: Dikranian A et al. Rheumatol Ther. 2021 (Dec 17). Doi: 10.1007/s40744-021-00405-w.